Determination of oxidative stress levels and some antioxidant enzyme activities in prostate cancer

References

• Aebi HE, Bergmeyer H. (Ed.). 1980. In: Oxidoreductases, transferases (Methods of enzymatic analysis Volume 3: Enzymes). Verlag Chemie, Deerfield Beach, FL, pp. 273–282.
   Google Scholar
• Torrealba N, Rodríguez-Berriguete G, Vera R, et al. Homeostasis: apoptosis and cell cycle in normal and pathological prostate. Aging Male. 2018;1–11. DOI:10.1080/13685538.2018.1470233
   PubMed Web of Science ®Google Scholar
• Clair DKS, Oberley TD, Ho YS. Overproduction of human Mn-superoxide dismutase modulates paraquat-mediated toxicity in mammalian cells. FEBS Lett. 1991;293:199–203.
   PubMed Web of Science ®Google Scholar
• Russo GI, Calogero AE, Condorelli RA, et al. Human papillomavirus and risk of prostate cancer: a systematic review and meta-analysis. Aging Male. 2018;23:7.
   Google Scholar
• Plastaras JP, Guengerich FP, Nebert DW, et al. Xenobiotic metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde. J Biol Chem. 2000;275:11784–11790.
   PubMed Web of Science ®Google Scholar
• Lykkesfeldt J, Viscovich M, Poulsen HE. Plasma malondialdehyde is induced by smoking: a study with balanced antioxidant profiles. BJN. 2004;92:203–206.
   PubMed Web of Science ®Google Scholar
• Poljsak B, Šuput D, Milisav I. Achieving the balance between ROS and antioxidants: when to use the synthetic antioxidants. Oxidative Med Cell long. 2013;2013:1.
   Web of Science ®Google Scholar
• Lü JM, Lin PH, Yao Q, et al. Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems. J Cell Mol Med. 2010;14:840–860.
   PubMed Web of Science ®Google Scholar
• Valko M, Izakovic M, Mazur M, et al. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004;266:37–56.
   PubMed Web of Science ®Google Scholar
• Çekiç SD, Çetinkaya A, Avan AN, et al. Correlation of total antioxidant capacity with reactive oxygen species (ROS) consumption measured by oxidative conversion. J Agric Food Chem. 2013;61:5260–5270.
   PubMed Web of Science ®Google Scholar
• Sandalio LM, Del Río LA. Localization of superoxide dismutase in glyoxysomes from Citrullus vulgaris. Functional implications in cellular metabolism. J PlantPhysiol. 1987;127:395–409.
   Web of Science ®Google Scholar
• Leone M, Cupane A, Militello V, et al. Fourier transform infrared analysis of the interaction of azide with the active site of oxidized and reduced bovine Cu, Zn superoxide dismutase. Biochemistry. 1998;37:4459–4464.
   PubMed Web of Science ®Google Scholar
• Teixeira HD, Schumacher RI, Meneghini R. Lower intracellular hydrogen peroxide levels in cells over expressing Cu Zn-superoxide dismutase. Proc Natl Acad Sci. 1998;95:7872–7875.
   PubMed Web of Science ®Google Scholar
• Urquiza-Salvat N, Pascual-Geler M, Lopez-Guarnido O, et al. Adherence to Mediterranean diet and risk of prostate cancer. Aging Male. 2018;1–7. DOI:10.1080/13685538.2018.1450854
   Web of Science ®Google Scholar
• López-Guarnido O, Urquiza-Salvat N, Saiz M, et al. Bioactive compounds of the Mediterranean diet and prostate cancer. Aging Male. 2018.27:10.
   Google Scholar
• Pascual-Geler M, Urquiza-Salvat N, Cozar JM, et al. The influence of nutritional factors on prostate cancer incidence and aggressiveness. Aging Male. 2018;21:31–39.
   PubMed Web of Science ®Google Scholar
• Russo GI, Di Mauro M, Regis F, et al. Association between dietary phytoestrogens intakes and prostate cancer risk in Sicily. Aging Male. 2018;21:48–54.
   PubMed Web of Science ®Google Scholar
• Deneke SM, Fanburg BL. Regulation of cellular glutathione. Am J Physiol. 1989;257:L163–L173.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay U, Das D, Banerjee RK. Reactive oxygen species: oxidative damage and pathogenesis. Curr Sci. 1999;658:666.
   Google Scholar
• Torrealba N, Rodriguez-Berriguete G, Fraile B, et al. PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer. Aging Male. 2018;1–12. DOI:10.1080/13685538.2018.1424130
   PubMed Web of Science ®Google Scholar
• Qian S, Xia J, Liu H, et al. Integrative transcriptome analysis identifies genes and pathways associated with enzalutamide resistance of prostate cancer. Aging Male. 2018;9:1–7.
   Web of Science ®Google Scholar
• Antonarakis ES, Feng Z, Trock BJ, et al. The natural history of metastatic progression in men with prostate‐specific antigen recurrence after radical prostatectomy: long term follow up. BJUinternational. 2012;109:32–39.
   Google Scholar
• Ewing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366:141–149.
   PubMed Web of Science ®Google Scholar
• Williams GM. DNA reactive and epigenetic carcinogens. Exp Toxicol Pathol. 1992;44:457–464.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer Facts & Figures 2016. Atlanta, Ga: American Cancer Society; 2016). Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 3601320–3601328.
   Google Scholar
• Molina-Garrido MJ, Guillén-Ponce C. Use of geriatric assessment and screening tools of frailty in elderly patients with prostate cancer. Review. Aging Male. 2017;20:102–109.
   PubMed Web of Science ®Google Scholar
• Jhan JH, Yang YH, Chang YH, et al. Hormone therapy for prostate cancer increases the risk of Alzheimer's disease: a nationwide 4-year longitudinal cohort study. Aging Male. 2017;20:33–38.
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Kinoshita H, Koito Y, et al. Preoperative sexual status of Japanese localized prostate cancer patients: comparison of sexual activity and EPIC scores. Aging Male. 2017;20:261–265.
   PubMed Web of Science ®Google Scholar
• Arivazhagan J, Nandeesha H, Dorairajan LN, et al. Association of elevated interleukin-17 and angiopoietin-2 with prostate size in benign prostatic hyperplasia. Aging Male. 2017;20:115–118.
   PubMed Web of Science ®Google Scholar
• Qian X, Xu D, Liu H, et al. Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the α-adrenergic receptor antagonist. Aging Male. 2017;20:250–256.
   PubMed Web of Science ®Google Scholar
• Ohwaki K, Endo F, Shimbo M, et al. Comorbidities as predictors of incidental prostate cancer after Holmium laser enucleation of the prostate: diabetes and high-risk cancer. Aging Male. 2017;20:257–260.
   PubMed Web of Science ®Google Scholar
• Teoh JY, Chiu PK, Chan SY, et al. Androgen deprivation therapy, diabetes and poor physical performance status increase fracture risk in Chinese men treated for prostate cancer. Aging Male. 2015;18:180–185.
   PubMed Web of Science ®Google Scholar
• Urushima H, Inomata-Kurashiki Y, Nishimura K, et al. The effects of androgen deprivation therapy with weight management on serum aP2 and adiponectin levels in prostate cancer patients. Aging Male. 2015;18:72–76.
   PubMed Web of Science ®Google Scholar
• Akbay E, Bozlu M, Çayan S, et al. Prostate-specific antigen decline pattern in advanced prostate cancer receiving androgen deprivation therapy and relationship with prostate-specific antigen progression. Aging Male. 2017;20:173–175.
   Web of Science ®Google Scholar
• Yassin A, Salman M, Talib RA, et al. Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register. Aging Male. 2017;20:125–133.
   PubMed Web of Science ®Google Scholar
• Efesoy O, Apa D, Tek M, et al. The effect of testosterone treatment on prostate histology and apoptosis in men with late-onset hypogonadism. Aging Male. 2016;19:79–84.
   PubMed Web of Science ®Google Scholar
• Grosman H, Fabre B, Lopez M, et al. Complex relationship between sex hormones, insulin resistance and leptin in men with and without prostatic disease. Aging Male. 2016;19:40–45.
   PubMed Web of Science ®Google Scholar
• Dong Z, Wang H, Xu M, et al. Intermittent hormone therapy versus continuous hormone therapy for locally advanced prostate cancer: a meta-analysis. Aging Male. 2015;18:233–237.
   PubMed Web of Science ®Google Scholar
• Canto P, Benítez Granados J, MartínezRamírez MA, et al. Genetic variants in ATP6 and ND3 mitochondrial genes are not associated with aggressive prostate cancer in Mexican-Mestizo men with overweight or obesity. Aging Male. 2016;19:187–191.
   PubMed Web of Science ®Google Scholar
• Morgia G, Castelli T, Privitera S, et al. Association between long-term erectile dysfunction and biochemical recurrence after permanent seed I(125) implant brachytherapy for prostate cancer. A longitudinal study of a single-institution. Aging Male. 2016;19:15–19.
   PubMed Web of Science ®Google Scholar
• Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39:44–84.
   PubMed Web of Science ®Google Scholar
• Slemmer JE, Shacka JJ, Sweeney MI, et al. Antioxidants and free radical scavengers for the treatment of stroke, traumatic brain injury and aging. Curr Med Chem. 2008;15:404–414.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. 2011. Treatment Choices for Men With Early-Stage Prostate Cancer. Retrieved 8–19, 2017 [cited 2017 Aug 19], Available from: https://www.cancer.gov/publications/patient-education/prostate-cancer-treatment-choices.pdf
   Google Scholar
• Karimi Galougahi K, Antoniades C, Nicholls SJ, et al. Redox biomarkers in cardiovascular medicine. Eur Heart J. 2015;36:1576–1582.
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Saglam K, Sonmez A, et al. Antioxidant system activation in prostate cancer. Bter. 2004;98:13.
   Google Scholar
• Yossepowitch O, Pinchuk I, Gur U, et al. Advanced but not localized prostate cancer is associated with increased oxidative stress. J Urol. 2007;178:1238–1244.
   PubMed Web of Science ®Google Scholar
• Camphausen K, Ménard C, Sproull M, et al. Isoprostane levels in the urine of patients with prostate cancer receiving radiotherapy are not elevated. Int J Radiat Oncol Biol Phys. 2004;58:1536–1539.
   PubMed Web of Science ®Google Scholar
• Barocas DA, Motley S, Cookson MS, et al. Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer. J Urol. 2011;185:2102–2107.
   PubMed Web of Science ®Google Scholar
• Brys M, Morel A, Forma E, et al. Relationship of urinary isoprostanes to prostate cancer occurence. Mol Cell Biochem. 2013;372:149–153.
   PubMed Web of Science ®Google Scholar
• Yang S, Pinney S.M, Mallick P, et al. Impact of oxidative stress biomarkers and carboxymethyllysine (an advanced glycation end product) on prostate cancer: a prospective study. Clin Genitourinary Cancer. 2015;13:e347–e351.
   PubMed Web of Science ®Google Scholar
• Rasool M, Khan SR, Malik A, et al. Comparative studies of salivary and blood sialic acid, lipid peroxidation and antioxidative status in Oral Squamous Cell Carcinoma (OSCC). Pak J Med Sci. 1969;30:466. ‏
   Google Scholar
• Lockett KL, Hall MC, Clark PE, et al. DNA damage levels in prostate cancer cases and controls. Carcinogenesis. 2006;27:1187–1193.
   PubMed Web of Science ®Google Scholar
• Sci JE, Valavanidis A, Vlachogianni T, Fiotakis C. 8-hydroxy-2′-deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C. 2009;27:120–139s.
   Google Scholar
• Surapaneni KM, Venkata GR. Lipid peroxidation and antioxidant status in patients with carcinoma of prostate. Indian J Physiol Pharmacol. 2006;50:350–354.
   PubMedGoogle Scholar
• Battisti V, Maders LD, Bagatini MD, et al. Oxidative stress and antioxidant status in prostate cancer patients: relation to Gleason score, treatment and bone metastasis. Biomed Pharmacother. 2011;65:516–524.
   PubMed Web of Science ®Google Scholar
• Woźniak A, Masiak R, Szpinda M, et al. Oxidative stress markers in prostate cancer patients after HDR brachytherapy combined with external beam radiation. Oxidative Medicine and Cellularlongevity. 2012;2012:1.
   Google Scholar
• Kotrikadze N, Alibegashvili M, Zibzibadze M, et al. Activity and content of antioxidant enzymes in prostate tumors. Exp Oncol. 2008;30:244–247.
   PubMedGoogle Scholar
• Pande D, Negi R, Karki K, et al. Simultaneous progression of oxidative stress, angiogenesis, and cell proliferation in prostate carcinoma. In: Urologic oncology: seminars and original investigations. Vol. 31, No. 8, pp. 1561–1566. Elsevier.
   Google Scholar
• Saydam N, Kirb A, Demir Ö, et al. Determination of glutathione, glutathione reductase, glutathione peroxidase and glutathione S-transferase levels in human lung cancer tissues. Cancer Lett. 1997;119:13–19.
   PubMed Web of Science ®Google Scholar
• Backos DS, Franklin CC, Reigan P. The role of glutathione in brain tumor drug resistance. Biochem Pharmacol. 2012;83:1005–1012.
   PubMed Web of Science ®Google Scholar
• Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene. 2003;22:7369.
   PubMed Web of Science ®Google Scholar